ELI Lilly and Company — Federal Contractor Profile
Eli Lilly and Company: $95.7 billion in Federal Contracts with No Recent Competitive Wins
Contractor Overview
Total Contract Value: $95,697,520,000 ($95.7B)
Total Awards: 74
Company Profile
Eli Lilly and Company is a global pharmaceutical company with a significant presence in federal government contracting, primarily through the provision of medical and pharmaceutical products and services. The company's core capabilities include drug development, manufacturing, and distribution, as well as support for medical research and clinical trials. Their extensive portfolio of government contracts reflects a broad range of services, from drug supply to research and development support. However, the absence of recent contracts and the lack of specific agency clients suggest a potential shift in their business strategy or a focus on long-term contracts. The company's substantial government business underscores its importance in the federal healthcare sector, but the absence of competitive contracts and the lack of detailed agency relationships raise questions about their market position and value to taxpayers.
Specializations
- Pharmaceutical drug development
- Drug manufacturing and supply
- Medical research and clinical trials
- Pharmaceutical distribution
- Healthcare support services
- Biotechnology research
- Pharmaceutical consulting
- Regulatory compliance services
- Pharmaceutical sales and marketing
- Pharmaceutical logistics and supply chain management
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: N/A (no recent contracts available)
Sole Source Rate: 100%
Recompete Rate: N/A (no recent contracts available)
Competitive Position
Eli Lilly and Company is a dominant player in the pharmaceutical sector, particularly in federal government contracting. Their sole-source contracts and lack of recent competitive wins suggest a strong market position and significant influence in the healthcare industry. However, the absence of detailed agency relationships and recent contracts may indicate a shift in their business strategy or a focus on long-term, high-value contracts.
Value to Taxpayers
Eli Lilly and Company's government contracts are substantial, but the lack of competitive contracts and the absence of recent contracts raise questions about their value to taxpayers. Their core capabilities in pharmaceuticals and medical research are essential, but the absence of competitive bidding and detailed agency relationships suggest potential risks in terms of cost and performance.
Agency Relationships
Eli Lilly and Company's lack of specific agency clients and recent contracts suggests a potential concentration risk. Without detailed information on their client base, it is difficult to assess the extent of their reliance on any particular agency. This concentration could pose risks if the company's primary clients experience budget cuts or changes in priorities.
Red Flags
- No recent competitive contracts: This suggests a lack of competition and potential for higher costs.
- Sole-source contracts: The absence of competitive contracts raises concerns about the company's market position and potential for cost escalation.
- Lack of detailed agency relationships: The absence of specific agency clients and recent contracts indicates a potential concentration risk.
- No recent contracts: This could indicate a shift in business strategy or a focus on long-term, high-value contracts, which may not provide the same level of transparency and oversight as competitive contracts.
Green Flags
- Significant government business: Eli Lilly and Company's substantial government contracts demonstrate their importance in the federal healthcare sector.
- Core capabilities: The company's expertise in pharmaceuticals, medical research, and drug development is essential for federal healthcare initiatives.
- No reported performance issues: The lack of reported performance issues suggests a strong track record and consistent service delivery.
Key Contracts
Eli Lilly and Company's government contracts span a wide range of services, from drug supply to research and development support. Their largest contracts often involve the supply of pharmaceuticals and medical supplies to federal agencies. For example, a recent contract with the Department of Defense (DoD) for the supply of pharmaceuticals and medical supplies highlights the company's role in supporting military healthcare. These contracts reveal the company's capabilities in pharmaceutical logistics and supply chain management, as well as their expertise in meeting the specific needs of federal agencies. However, the absence of recent competitive contracts and the lack of detailed agency relationships suggest potential risks in terms of cost and performance. The company's focus on long-term, high-value contracts may provide stability but may also limit transparency and oversight.
Frequently Asked Questions
What does ELI LILLY AND COMPANY do for the federal government?
Eli Lilly and Company provides a wide range of pharmaceutical and medical services to the federal government, including drug development, manufacturing, and supply, as well as support for medical research and clinical trials. Their core capabilities are essential for federal healthcare initiatives, and their contracts often involve the supply of pharmaceuticals and medical supplies to various agencies, such as the Department of Defense and the Department of Veterans Affairs.
How much taxpayer money does ELI LILLY AND COMPANY receive?
Eli Lilly and Company has received a total of $95.7 billion in government contracts, with an average contract size of $129,32,09,730. The company's substantial government business underscores its importance in the federal healthcare sector, but the lack of recent competitive contracts and the absence of detailed agency relationships raise questions about the value of this spending to taxpayers.
Is ELI LILLY AND COMPANY good value for taxpayer money?
Eli Lilly and Company's government contracts are substantial, but the lack of competitive contracts and the absence of recent contracts raise questions about their value to taxpayers. Their core capabilities in pharmaceuticals and medical research are essential, but the absence of competitive bidding and detailed agency relationships suggest potential risks in terms of cost and performance. The company's focus on long-term, high-value contracts may provide stability but may also limit transparency and oversight.
How does ELI LILLY AND COMPANY win its contracts?
Eli Lilly and Company primarily wins its government contracts through sole-source contracts, as there are no recent competitive contracts available. This suggests a strong market position and significant influence in the healthcare industry. However, the absence of detailed agency relationships and recent contracts may indicate a shift in their business strategy or a focus on long-term, high-value contracts, which may not provide the same level of transparency and oversight as competitive contracts.
What agencies use ELI LILLY AND COMPANY most?
Eli Lilly and Company's lack of specific agency clients and recent contracts suggests a potential concentration risk. Without detailed information on their client base, it is difficult to assess the extent of their reliance on any particular agency. This concentration could pose risks if the company's primary clients experience budget cuts or changes in priorities.
What are the risks of relying on ELI LILLY AND COMPANY?
The risks of relying on Eli Lilly and Company include the absence of competitive contracts, which may lead to higher costs and limited transparency. The lack of detailed agency relationships and recent contracts suggests potential concentration risks, as the company may be heavily reliant on a few key clients. Additionally, the absence of recent competitive wins and the focus on long-term, high-value contracts may limit oversight and accountability.
How does ELI LILLY AND COMPANY compare to similar contractors?
Eli Lilly and Company is a dominant player in the pharmaceutical sector, particularly in federal government contracting. Their sole-source contracts and lack of recent competitive wins suggest a strong market position and significant influence in the healthcare industry. However, the absence of detailed agency relationships and recent contracts may indicate a shift in their business strategy or a focus on long-term, high-value contracts, which may not provide the same level of transparency and oversight as competitive contracts. Compared to other pharmaceutical companies, Eli Lilly and Company's focus on long-term contracts and lack of recent competitive wins may set them apart, but the lack of detailed agency relationships and recent contracts raises questions about their market position and value to taxpayers.
Recent Federal Contracts
ELI Lilly and Company has 5 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| DoD Awards $1.46 Billion for BEBTELOVIMAB to Eli Lilly, Raising Questions on ... | Department of Defense | $1.5B | N/A |
| DoD awards $1.37B for Monoclonal Antibody LY-COV555, a sole-source pharmaceut... | Department of Defense | $1.4B | N/A |
| DoD awards $1.29B for 614K monoclonal antibody doses from Eli Lilly | Department of Defense | $1.3B | N/A |
| DoD Awards $330M for 388K Monoclonal Antibody Doses to Eli Lilly | Department of Defense | $329.8M | N/A |
| DoD awards $210M for 100,000 doses of Combination Monoclonal Antibody from El... | Department of Defense | $210.0M | N/A |